سعر باكليتاكس 150مجم فيال 2026

Paclitax 150 mg vial: paclitaxel 150 mg for intravenous infusion by Cipla Ltd. (India), marketed by Star International Company; 1 vial. Antineoplastic taxane.

• Advanced ovarian carcinoma (first-line with cisplatin, and subsequent therapy)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjuvant treatment of node-positive breast cancer after doxorubicin-containing chemotherapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Common: anaemia/neutropenia, alopecia, peripheral neuropathy, arthralgia/myalgia, nausea and vomiting, hypersensitivity reactions; oedema in about 21%.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to paclitaxel or drugs formulated in polyoxyl 35 castor oil; baseline neutrophils <1,500 cells/mm3 in solid tumours (<1,000 in AIDS-related Kaposi sarcoma).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Anaphylaxis and severe hypersensitivity reactions (2-4% in trials, some fatal) despite premedication; do not rechallenge after severe reactions.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Dose-dependent bone marrow suppression (mainly neutropenia) is dose-limiting; neutrophil nadir at a median of 11 days.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm; embryo- and fetotoxicity in rabbits; no adequate studies in pregnant women.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk; nursing should be discontinued during paclitaxel therapy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Paclitaxel: Promotes microtubule assembly from tubulin dimers and stabilises microtubules against depolymerisation, disrupting the microtubule network needed for mitosis.